-
摘要: 心脏移植是目前终末期心力衰竭最有效的治疗手段,但供者短缺问题日益严峻。近年来,快速发展的机械循环支持技术为终末期心力衰竭患者提供了多种治疗选择。心室辅助装置(VAD)作为一种重要的机械循环支持,根据辅助时长可分为持久VAD(dVAD)和临时VAD(tVAD),其中dVAD在桥接心脏移植、终点治疗、为临床决策争取时间方面展现了良好的应用价值。随着技术的进步和临床应用经验的积累,VAD朝着更具生物相容性、更轻量化、更仿生、更智能的方向发展。本文主要对VAD发展历程、国内外应用现状及笔者单位VAD整体应用情况进行综述,以期为促进我国VAD的临床应用提供参考。Abstract: At present, heart transplantation is the most effective treatment for end-stage heart failure. Nevertheless, the shortage of donors is becoming an increasingly severe challenge. In recent years, rapid development of mechanical circulatory support technologies has provided multiple therapeutic options for patients with end-stage heart failure. As an important mechanical circulatory support device, ventricular assist device (VAD) are divided into durable VAD (dVAD) and temporary VAD (tVAD) according to the duration of assistance. dVAD shows application potential in bridging heart transplantation, destination therapy and bridge to decision. With technological progress and experience accumulation in clinical application, VAD is evolving towards the direction of more biocompatible, lighter, more bionic and intelligent. In this article, the development of VAD, application status at home and abroad and the overall application of VAD in our hospital were reviewed, aiming to provide reference for promoting the clinical application of VAD in China.
-
表 1 已通过美国FDA认证的VAD与国产VAD
Table 1. VAD certified by FDA and domestic VAD
VAD 转速(转/分) 转子类型 体内泵体质量 目前进展 已通过美国FDA认证dVAD HeartMateⅡ 6 000~15 000 轴流离心式 暂无相关资料 已上市 HeartWare HVAD 2 400~3 200 磁悬浮离心式 暂无相关资料 已退市 HeartMateⅢ 3 000~9 000 磁悬浮离心式 暂无相关资料 已上市 国产dVAD EVAHEART 1 800~2 200 磁液悬浮搏动式 262 g 已上市 CH-VAD 2 500~3 100 磁悬浮离心式 180 g 已上市 HeartCon 2 000~3 400 磁悬浮离心式 185 g 临床试验 CorHeart 6 2 200~4 300 磁悬浮离心式 90 g 临床试验 -
[1] RAJAB TK, JAGGERS J, CAMPBELL DN. Heart transplantation following donation after cardiac death: history, current techniques, and future[J]. J Thorac Cardiovasc Surg, 2021, 161(4): 1335-1340. DOI: 10.1016/j.jtcvs.2020.02.085. [2] CAMELI M, PASTORE MC, CAMPORA A, et al. Donor shortage in heart transplantation: how can we overcome this challenge?[J]. Front Cardiovasc Med, 2022, 9: 1001002. DOI: 10.3389/fcvm.2022.1001002. [3] 段正伟, 刘云霏. 常规供心与边缘供心在终末期心脏病心脏移植中的应用[J]. 中国组织工程研究, 2022, 26(26): 4211-4215. https://www.cnki.com.cn/Article/CJFDTOTAL-XDKF202226019.htmDUAN ZW, LIU YF. Conventional versus marginal donor heart transplantation in patients with end-stage heart disease[J]. Chin J Tissue Eng Res, 2022, 26(26): 4211-4215. https://www.cnki.com.cn/Article/CJFDTOTAL-XDKF202226019.htm [4] GUSTAFSSON F, ROGERS JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes[J]. Eur J Heart Fail, 2017, 19(5): 595-602. DOI: 10.1002/ejhf.779. [5] 胡盛寿. 心室辅助装置治疗心力衰竭现状和未来思考[J]. 中华心力衰竭和心肌病杂志, 2022, 6(2): 77-79. DOI: 10.3760/cma.j.cn101460-20220829-00078.HU SS. Current status and future considerations for ventricular assist devices in the treatment of heart failure[J]. Chin J Heart Fail Cardiomyopathy, 2022, 6(2): 77-79. DOI: 10.3760/cma.j.cn101460-20220829-00078. [6] PRINZING A, HEROLD U, BERKEFELD A, et al. Left ventricular assist devices-current state and perspectives[J]. J Thorac Dis, 2016, 8(8): E660-E666. DOI: 10.21037/jtd.2016.07.13. [7] DEBAKEY ME. Left ventricular bypass pump for cardiac assistance. clinical experience[J]. Am J Cardiol, 1971, 27(1): 3-11. DOI: 10.1016/0002-9149(71)90076-2. [8] MOAZAMI N, FUKAMACHI K, KOBAYASHI M, et al. Axial and centrifugal continuous-flow rotary pumps: a translation from pump mechanics to clinical practice[J]. J Heart Lung Transplant, 2013, 32(1): 1-11. DOI: 10.1016/j.healun.2012.10.001. [9] KRABATSCH T, SCHWEIGER M, DANDEL M, et al. Is bridge to recovery more likely with pulsatile left ventricular assist devices than with nonpulsatile-flow systems?[J]. Ann Thorac Surg, 2011, 91(5): 1335-1340. DOI: 10.1016/j.athoracsur.2011.01.027. [10] KIRKLIN JK, PAGANI FD, KORMOS RL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events[J]. J Heart Lung Transplant, 2017, 36(10): 1080-1086. DOI: 10.1016/j.healun.2017.07.005. [11] Evaheart technology - applied medical science — rotary pump yet pulsatile[EB/OL]. [2022-11-14]. https://www.evaheart-usa.com/projects [12] MOLINA EJ, SHAH P, KIERNAN MS, et al. The Society of Thoracic Surgeons Intermacs 2020 Annual Report[J]. Ann Thorac Surg, 2021, 111(3): 778-792. DOI: 10.1016/j.athoracsur.2020.12.038. [13] HeartMate 3 LVAD[EB/OL]. [2022-11-14]. https://www.cardiovascular.abbott/us/en/hcp/products/heart-failure/left-ventricular-assist-devices/heartmate-3/about.html. [14] SCHMITTO JD, HANKE JS, ROJAS SV, et al. First implantation in man of a new magnetically levitated left ventricular assist device (HeartMate Ⅲ)[J]. J Heart Lung Transplant, 2015, 34(6): 858-860. DOI: 10.1016/j.healun.2015.03.001. [15] MEHRA MR, GOLDSTEIN DJ, CLEVELAND JC, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial[J]. JAMA, 2022, 328(12): 1233-1242. DOI: 10.1001/jama.2022.16197. [16] CHO SM, MEHAFFEY JH, MEYERS SL, et al. Cerebrovascular events in patients with centrifugal-flow left ventricular assist devices: propensity score-matched analysis from the Intermacs Registry[J]. Circulation, 2021, 144(10): 763-772. DOI: 10.1161/CIRCULATIONAHA.121.055716D. [17] STEHLIK J, EDWARDS LB, KUCHERYAVAYA AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report—2012[J]. J Heart Lung Transplant, 2012, 31(10): 1052-1064. DOI: 10.1016/j.healun.2012.08.002. [18] VARSHNEY AS, DEFILIPPIS EM, COWGER JA, et al. Trends and outcomes of left ventricular assist device therapy: JACC focus seminar[J]. J Am Coll Cardiol, 2022, 79(11): 1092-1107. DOI: 10.1016/j.jacc.2022.01.017. [19] NESTA M, CAMMERTONI F, BRUNO P, et al. Implantable ventricular assistance systems (VAD) as a bridge to transplant or as 'destination therapy'[J]. Eur Heart J Suppl, 2021, 23(Suppl E): E99-E102. DOI: 10.1093/eurheartj/suab101. [20] HAN JJ, ELZAYN H, DUDA MM, et al. Heart transplant waiting list implications of increased ventricular assist device use as a bridge strategy: a national analysis[J]. Artif Organs, 2021, 45(4): 346-353. DOI: 10.1111/aor.13833. [21] MEHRA MR, CRANDALL DL, GUSTAFSSON F, et al. Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial[J]. Eur J Heart Fail, 2021, 23(7): 1226-1237. DOI: 10.1002/ejhf.2275. [22] MEHRA MR, CLEVELAND JC JR, URIEL N, et al. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants[J]. Eur J Heart Fail, 2021, 23(8): 1392-1400. DOI: 10.1002/ejhf.2211. [23] 永仁心·植入式左心室辅助装置[EB/OL]. [2022-11-14]. http://www.evaheart.com.cn/. [24] 同心医疗[EB/OL]. [2022-11-14]. https://www.chbiomedical.com/. [25] 马露, 程兆云, 侯剑峰, 等. 全磁悬浮左心室辅助装置的研究进展[J]. 中国心血管病研究, 2021, 19(3): 247-251. DOI: 10.3969/j.issn.1672-5301.2021.03.011.MA L, CHENG ZY, HOU JF, et al. Advance in full magnetic levitation left ventricular assist device[J]. Chin J Cardiovasc Res, 2021, 19(3): 247-251. DOI: 10.3969/j.issn.1672-5301.2021.03.011. [26] 陈娟, 杨潇逸, 卢岩, 等. 全球心室辅助装置科学研究态势分析[J]. 中国医学装备, 2022, 19(1): 2-7. DOI: 10.3969/J.ISSN.1672-8270.2022.01.001.CHEN J, YANG XY, LU Y, et al. Analysis on the situation and trend of scientific researches of global VAD[J]. China Med Equip, 2022, 19(1): 2-7. DOI: 10.3969/J.ISSN.1672-8270.2022.01.001. [27] 严舒, 陈娟, 卢岩, 等. 国内外植入式心室辅助装置研发与应用进展[J]. 中国医学装备, 2022, 19(1): 21-26. DOI: 10.3969/J.ISSN.1672-8270.2022.01.005.YAN S, CHEN J, LU Y, et al. Progress of development and application of implantable VAD of domestic and overseas[J]. China Med Equip, 2022, 19(1): 21-26. DOI: 10.3969/J.ISSN.1672-8270.2022.01.005. [28] 林颖, 石琳. 机械辅助循环治疗心力衰竭[J]. 国际心血管病杂志, 2021, 48(2): 81-86. DOI: 10.3969/j.issn.1673-6583.2021.02.005.LIN Y, SHI L. Mechanically assisted circulation for heart failure[J]. Int J Cardiovasc Dis, 2021, 48(2): 81-86. DOI: 10.3969/j.issn.1673-6583.2021.02.005. [29] 彭战, 华琨, 周元, 等. 心力衰竭后心室辅助装置应用历史与展望[J]. 中华胸心血管外科杂志, 2021, 37(9): 572-576. DOI: 10.3760/cma.j.cn112434-20200603-00279.PENG Z, HUA K, ZHOU Y, et al. Application of ventricular assist devices after heart failure: history and prospect[J]. Chin J Thorac Cardiovasc Surg, 2021, 37(9): 572-576. DOI: 10.3760/cma.j.cn112434-20200603-00279. [30] 中国心衰中心联盟, 苏州工业园区心血管健康研究院, 中国心血管健康联盟. 中国心衰中心工作报告(2021)——心力衰竭患者的诊疗现况[J]. 中国介入心脏病学杂志, 2022, 30(5): 328-336. DOI: 10.3969/j.issn.1004-8812.2022.05.002.China Heart Failure Center Alliance, Suzhou Industrial Park Cardiovascular Health Research Institute, China Cardiovascular Health Alliance. Work Report of China Heart Failure Center (2021) - current status of diagnosis and treatment of patients with heart failure[J]. Chin J Interv Cardiol, 2022, 30(5): 328-336. DOI: 10.3969/j.issn.1004-8812.2022.05.002.